
Press Release

June 20, 2023

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Change in Name of Wholly Owned Subsidiary Companies

Sumitomo Pharma Co., Ltd. (the “Company”) (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that on June 19, 2023 (local time), it decided to change the names of its wholly owned subsidiary companies in connection with the combination announced in the press release dated April 3, 2023, entitled “Sumitomo Pharma Announces the Combination of Group Companies in the U.S.,” as described below.

1. Details Regarding the Change of Company Names

The name of the remaining company after the combination of Group companies in the U.S. will be changed from Sunovion Pharmaceuticals Inc. to Sumitomo Pharma America, Inc. The name of the UK holding company will be changed from Sumitovant Biopharma Ltd. to Sumitomo Pharma UK Holdings, Ltd.

2. Reason for the Change

On the occasion of the combination of its Group companies in the U.S., the Company has decided to change the names of the two companies to unify the corporate brand as one of the Group companies.

3. Date of the Change

July 1, 2023

4. Overview of Sunovion Pharmaceuticals Inc. and Sumitovant Biopharma Ltd.

(1) Sunovion Pharmaceuticals Inc.

Company Name	Sunovion Pharmaceuticals Inc.
Head Office	Marlborough, MA, U.S.A.
Representative	Antony Loebel, President and Chief Executive Officer
Description of Business	Manufacturing and sale of pharmaceuticals
Capital	US\$0.01
Date of Establishment	January 1984
Major Shareholder and Shareholding Ratio	Sumitomo Pharma America Holdings, Inc. 100% (100% sub-subsidiary of Sumitomo Pharma Co., Ltd.)

(2) Sumitovant Biopharma Ltd.

Company Name	Sumitovant Biopharma Ltd.
Head Office	London, UK

Representative	Monika Adams, Transactions Officer
Description of Business	Holding company, management of Sumitovant group companies and formulation and promotion of business strategies, etc.
Capital	US\$2,000
Date of Establishment	October 2019
Major Shareholder and Shareholding Ratio	100% subsidiary of Sumitomo Pharma Co., Ltd.

* For the press release dated April 3, 2023, entitled “Sumitomo Pharma Announces the Combination of Group Companies in the U.S.,” please see below.

<https://www.sumitomo-pharma.com/news/20230403.html>

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp